Back to Newsroom

Arena Pharmaceuticals’ APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.

Click here to read more